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ABSTRACT 
Genome-wide association studies have identified breast cancer risk variants in over 150 
genomic regions, but the mechanisms underlying risk remain largely unknown. These regions 
were explored by combining association analysis with in silico genomic feature annotations. 
We defined 205 independent risk-associated signals with the set of credible causal variants 
(CCVs) in each one. In parallel, we used a Bayesian approach (PAINTOR) that combines genetic 
association, linkage disequilibrium, and enriched genomic features to determine variants with 
high posterior probabilities of being causal. Potentially causal variants were significantly over-
represented in active gene regulatory regions and transcription factor binding sites. We 
applied our INQUSIT pipeline for prioritizing genes as targets of those potentially causal 
variants, using gene expression (eQTL), chromatin interaction and functional annotations. 
Known cancer drivers, transcription factors and genes in the developmental, apoptosis, 
immune system and DNA integrity checkpoint gene ontology pathways, were over-
represented among the highest confidence target genes. 
INTRODUCTION 
Genome-wide association studies (GWAS) have identified genetic variants associated with 
breast cancer risk in more than 150 genomic regions 1,2. However, the variants and genes 
driving these associations are mostly unknown, with fewer than 20 regions studied in detail 
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3-20. Here, we aimed to fine-map all known breast cancer susceptibility regions using dense 
genotype data on > 217K subjects participating in the Breast Cancer Association Consortium 
(BCAC) and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). All samples 
were genotyped using the OncoArrayTM 1,2,21 or the iCOGS chip 22,23. Stepwise multinomial 
logistic regression was used to identify independent association signals in each region and 
define credible causal variants (CCVs) within each signal. We found genomic features 
significantly overlapping the CCVs. We then used a Bayesian approach, integrating genomic 
features and genetic associations, to refine the set of likely causal variants and calculate their 
posterior probabilities. Finally, we integrated genetic and in silico epigenetic, expression and 
chromatin conformation data to infer the likely target genes of each signal. 
 
RESULTS 
Most breast cancer genomic regions contain multiple independent risk-associated signals 
We included 109,900 breast cancer cases and 88,937 controls, all of European ancestry, from 
75 studies in the BCAC. Genotypes (directly observed or imputed) were available for 639,118 
single nucleotide polymorphisms (SNPs), deletion/insertions, and copy number variants 
(CNVs) with minor allele frequency (MAF) ≥ 0.1% within 152, previously defined, risk-
associated regions (Supplementary Table 1; Figure 1). Multivariate logistic regression 
confirmed associations for 150/152 regions at a p-value < 10-4 significance threshold 
(Supplementary Table 2A). To determine the number of independent risk signals within each 
region we applied stepwise multinomial logistic regression, deriving the association of each 
variant, conditional on the more significant ones, in order of statistical significance. Finally, 
we defined CCVs in each signal as variants with conditional p-values within two orders of 
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magnitude of the index variant 24. We classified the evidence for each independent signal, 
and its CCVs, as either strong (conditional p-values <10-6) or moderate (10-6 < conditional p-
values <10-4). 
 
From the 150 genomic regions we identified 352 independent risk signals containing 13,367 
CCVs, 7,394 of these were within the 196 strong-evidence signals across 129 regions (Figures 
2A-B). The number of signals per region ranged from 1 to 11, with 79 (53%) containing 
multiple signals. We noted a wide range of CCVs per signal, but in 42 signals there was only a 
single CCV: for these signals, the simplest hypothesis is that the CCV is causal (Figures 2C-D, 
Table 1). Furthermore, within signals with few CCVs (<10), the mean scaled CADD score was 
higher than in signals with more CCVs (13.1 Vs 6.7 for CCVs in exons; Pttest = 2.7x10-4) 
suggesting that these are more likely to be functional. 
 
The majority of breast tumors express the estrogen receptor (ER-positive), but ~20% do not 
(ER-negative); these two tumor types have distinct biological and clinical characteristics 25. 
Using a case-only analysis for the 196 strong-evidence signals, we found 66 signals (34%; 
containing 1,238 CCVs) where the lead variant conferred a greater relative-risk of developing 
ER-positive tumors (false discovery rate, FDR 5%), and 29 (15%; 646 CCVs) where the lead 
variant conferred a greater risk of ER-negative cancer tumors (FDR 5%) (Supplementary Table 
2B, Figure 2E). The remaining 101 signals (51%, 5,510 CCVs) showed no difference by ER 
status (referred to as ER-neutral). 
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Patients with BRCA1 mutations are more likely to develop ER-negative tumors 26. Hence, to 
increase our power to identify ER-negative signals, we performed a fixed-effects meta-
analysis, combining association results from BRCA1 mutation carriers in CIMBA with the BCAC 
ER-negative association results. This meta-analysis identified ten additional signals, seven ER-
negative and three ER-neutral, making 206 strong-evidence signals (17% ER-negative) 
containing 7,652 CCVs in total (Figure 2F). More than one quarter of the CCVs (2,277) were 
accounted for by one signal, resulting from strong linkage disequilibrium with a copy number 
variant. The remaining analyses focused on the other 205 strong signals across 128 regions 
(Supplementary Table 2C). 
The proportion of the familial relative risk of breast cancer (FRR) explained by all 206 strong 
signals was 20.6%, compared with 17.6% when only the lead SNP for each region was 
considered. The proportion of the FRR explained increased by a further 3% (to 23.6%) when 
all 352 signals were considered (Supplementary Table 2D). 
CCVs are over-represented in active gene-regulatory regions and transcription factor 
binding sites (TFBSs) 
We constructed a database of mapped genomic-features in seven primary cells derived from 
normal breast and 19 breast cell lines using publicly available data, resulting in 811 annotation 
tracks in total. These ranged from general features, such as whether a variant was in an exon 
or in open chromatin, to more specific features, such a cell-specific TF binding or histone mark 
(determined through ChIP-Seq experiments) in breast-derived cells or cell lines. Using logistic 
regression, we examined the overlap of these genomic-features with the positions of 5,117 
CCVs in the 195 strong-evidence BCAC signals versus the positions of 622,903 variants 
excluded as credible candidates in the same regions (Supplementary Figure 1A, 
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Supplementary Table 3). We found significant enrichment of CCVs (FDR 5%) in the following 
genomic-features: 
 
(i) Open chromatin (determined by DNase-seq and FAIRE-seq) in ER-positive breast cancer 
cell-lines and normal breast (Figure 3A). Conversely, we found depletion of CCVs within 
heterochromatin (determined by the H3K9me3 mark in normal breast, and by chromatin-
state in ER-positive cells 27). 
 
(ii) Actively transcribed genes in normal breast and ER-positive cell lines (defined by 
H3K36me3 or H3K79me2 histone marks, Figure 3A). Enrichment was larger for ER-neutral 
CCVs than for those affecting either ER-positive or ER-negative tumors. 
 
(iii) Gene regulatory regions. CCVs overlapped distal gene regulatory elements in ER-positive 
breast cancer cells lines (defined by H3K4me1 or H3K27ac marks, Figure 3B). This was 
confirmed using the ENCODE definition of active enhancers in MCF-7 cells (enhancer-like 
regions defined by combining DNase and H3K27ac marks), as well as the definition of 28 and 
27 (Supplementary Table 3). Under these more stringent definitions, enrichment among ER-
positive CCVs was significantly larger than ER-negative or ER-neutral CCVs. Data from 27, 
showed that 73% of active enhancer regions overlapped by ER-positive CCVs in ER-positive 
cells (MCF-7), are inactive in the normal HMEC breast cell line; thus, these enhancers appear 
to be MCF-7-specific. 
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We also detected significant enrichment of CCVs in active promoters in ER-positive cells 
(defined by H3K4me3 marks in T-47D), although the evidence for this effect was weaker than 
for distal regulatory elements (defined by H3K27ac marks in MCF-7, Figure 3B). Only ER-
positive CCVs were significantly enriched in T-47D active promoters. Conversely, CCVs were 
depleted among repressed gene-regulatory elements (defined by H3K27me3 marks) in 
normal breast (Figure 3B). As a control, we performed similar analyses with autoimmune 
disease CCVs 29 (Methods) and relevant B and T cells (Figures 3B-E). The strongest evidence 
of enrichment of breast cancer CCVs was found at regulatory regions active in ER-positive 
cells (Figure 3B), whereas enrichment of autoimmune CCVs was in regulatory regions active 
in B and T cells (Figure 3E). We also compared the enrichment of our CCVs in enhancer-like 
and promoter-like regions (defined by ENCODE; Supplementary Figure 1B). The strongest 
evidence of enrichment of ER-positive CCVs in enhancer-like regions was found in MCF-7 cells, 
the only ER-positive cell line in ENCODE (Supplementary Figure 1B). These results highlight 
both the tissue- and disease-specificity of these histone marked gene regulatory regions. 
 
(iv) We observed significant enrichment of CCVs in the binding sites for 40 TFBSs determined 
by ChIP-Seq (Figures 3F-H). The majority of the experiments were performed in ER-positive 
cell lines (90 TFBSs, 20 with data in ER-negative cell lines, 76 in ER-positive cell lines, and 16 
in normal breast). These TFBSs overlap each other and histone marks of active regulatory 
regions (Supplementary Figure 2). Enrichment in five TFBSs (ESR1, FOXA1, GATA3, TCF7L2, 
E2F1) has been previously reported 2,30. All 40 TFBSs were significantly enriched in ER-positive 
CCVs (Figure 3F), seven were also enriched in ER-negative CCVs and nine in ER-neutral CCVs 
(Figures 3G-H). ESR1, FOXA1, GATA3 and EP300 TFBSs were enriched in all CCV ER-subtypes. 
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However, the enrichment for ESR1, FOXA1 or GATA3 was stronger for ER-positive CCVs than 
for ER-negative or ER-neutral. 
 
CCVs significantly overlap consensus transcription factor binding motifs 
We investigated whether CCVs were also enriched within consensus TF binding motifs by 
conducting a motif-search within active regulatory regions (ER-positive CCVs at H3K4me1 
marks in MCF-7). We identified 30 motifs, from eight TF families, with enrichment in ER-
positive CCVs (FDR 10%, Supplementary Table 4A) and a further five motifs depleted among 
ER-positive CCVs. To assess whether the motifs appeared more frequently than by chance at 
active regulatory regions overlapped by our ER-positive CCVs, we compared motif-presence 
in a set of randomized control sequences (Methods). Thirteen of 30 motifs were more 
frequent at active regulatory regions with ER-positive CCV enrichment; these included seven 
homeodomain motifs and two fork head factors (Supplementary Table 4B). 
 
When we looked at the change in predicted binding affinity, 57 ER-positive signals (86%) 
included at least one CCV predicted to modify the binding affinity of the enriched TFBSs (≥2-
fold, Supplementary Table 4C). Forty-eight ER-positive signals (73%) had at least one CCV 
predicted to modify the binding affinity >10-fold. This analysis validates previous reports of 
breast cancer causal variants that alter DNA binding affinity for FOXA1 3,30 
 
Bayesian fine -mapping incorporating functional annotations and linkage disequilibrium 
As an alternative statistical approach for inferring likely causal variants, we applied PAINTOR 
31 to the same 128 regions (Figure 1). In brief, PAINTOR integrates genetic association results, 
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linkage disequilibrium (LD) structure, and enriched genomic features in an empirical Bayes 
framework and derives the posterior probability (PP) of each variant being causal, conditional 
on available data. To eliminate artifacts due to differences in genotyping and imputation 
across platforms, we restricted PAINTOR analyses to cases and controls typed using the 
OncoArray (61% of the total). We identified seven variants with high posterior probability 
(HPP ≥ 80%) of being causal for overall breast cancer and ten for the ER-positive subtype 
(Table 1); two of these had HPP > 80% for both ER-positive and overall breast cancer. These 
15 HPP variants (HPPVs; ≥ 80%) were distributed across 13 regions. We also identified an 
additional 35 variants in 25 regions with HPP (≥ 50% and < 80%) for ER-positive, ER-negative, 
or overall breast cancer (Figure 2G).  
 
Consistent with the CCV analysis, we found evidence that most regions contained multiple 
HPPVs; the sum of PP across all variants in a region (an estimate of the number of distinct 
causal variants in the region) was > 2.0 for 84/86 regions analyzed for overall breast cancer, 
with a maximum of 16.1 and a mean of 6.4. For ER-positive cancer, 46/47 regions had total 
PP > 2.0 (maximum 18.3, mean 6.5) and for ER-negative, 17/23 regions had total PP > 2.0 
(maximum 9.1, mean 3.2). 
 
Although for many regions we were not able to identify HPP variants, we were able to reduce 
the proportion of variants needed to account for 80% of the total PP in a region to under 5% 
for 65 regions for overall, 43 for ER-positive, and 18 for ER-negative breast cancer 
(Supplementary Figure 3A-C). PAINTOR analyses were also able to reduce the set of likely 
causal variants in many cases. After summing the PPs for CCVs in each of the overall breast 
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cancer signals, 39/100 strong-evidence signals had a total PP > 1.0. The number of CCVs in 
these signals ranged from 1 to 375 (median 24), but the number of variants needed to capture 
95% of the total PP in each signal ranged from 1 to 115 (median 12), representing an average 
reduction of 43% in the number of variants needed to capture the signal. 
 
PAINTOR and CCV analyses were generally consistent, yet complementary. Only 3.3% of 
variants outside of the set of strong-signal CCVs for overall breast cancer had PP > 1%, and 
only 48 (0.013%) of these had PP > 30% (Supplementary Figure 3D). At ER-positive and ER-
negative signals respectively, 3.1% and 1.6% of the non-CCVs at strong signals had PP > 1%, 
and 40 (0.019%) and 3 (0.003%) of these had PP > 30% (Figures S3E-F). For the non-CCVs at 
strong-evidence signals with PP > 30%, the relatively high PP may be driven by the addition 
of functional annotation. Indeed, the incorporation of functional annotations more than 
doubled the PP for 64/88 variants when compared to a PAINTOR model with no functional 
annotations.  
 
CCVs co-localize with variants controlling local gene expression 
We used four breast-specific expression quantitative trait loci (eQTL) data sets to identify a 
credible set of variants associated with differences in gene expression (eVariants): tumor 
tissue from the Nurses’ Health Study (NHS) 32 and The Cancer Genome Atlas (TCGA) 33, and 
normal breast tissue from the NHS and the Molecular Taxonomy of Breast Cancer 
International Consortium (METABRIC) 34. We then examined the overlap of eVariants (for 
each gene eVariants were defined as those variants that had a p-value within two orders of 
magnitude of the variant most significantly associated with that gene’s expression) with CCVs 
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(Methods). There was significant overlap of CCVs with eVariants from both the NHS normal 
and breast cancer tissue studies (normal breast OR = 2.70, p-value = 1.7×10-5; tumor tissue 
OR = 2.34, p-value = 2.6×10-4; Supplementary Table 3). ER-neutral CCVs overlapped with 
eVariants in normal tissue more frequently than did ER-positive and ER-negative CCVs (ORER-
neutral = 3.51, p-value = 1.3×10-5). Cancer risk CCVs overlapped credible eVariants in 128/205 
(62%) signals in at least one of the datasets (Supplementary Table 5A-B). Sixteen additional 
variants with PP ≥ 30%, not included among the CCVs, also overlapped with a credible 
eVariant (Supplementary Table 5A-B). 
 
Transcription factors and known somatic breast cancer drivers are overrepresented among 
prioritized target genes  
We assumed that causal variants function by affecting the behavior of a local target gene. 
However, it is challenging to define target genes or to determine how they may be affected 
by the causal variant. Few potentially causal variants directly affect protein coding: we 
observed 67/5,375 CCVs, and 19/137 HPPVs (≥ 30%) in protein-coding regions. Of these, 33 
(0.61%) were predicted to create a missense change, one a frameshift, and another a stop-
gain, while 30 were synonymous (0.59%, Supplementary Table 5C). Four hundred and ninety-
nine CCVs at 94 signals, and four additional HPPV (≥ 30%), are predicted to create new splice 
sites or activate cryptic splice sites in 126 genes (Supplementary Table 5D). These results are 
consistent with previous observations that majority of common susceptibility variants are 
regulatory. 
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We applied an updated version of our pipeline INQUISIT - integrated expression quantitative 
trait and in-silico prediction of GWAS targets) 2 to prioritize potential target genes from 5,375 
CCVs in strong signals and all 138 HPPVs (≥ 30%; Supplementary Table 2C). The pipeline 
predicted 1,204 target genes from 124/128 genomic regions examined. As a validation we 
examined the overlap between INQUISIT predictions and 278 established breast cancer driver 
genes 35-39. Cancer driver genes were over-represented among high confidence (Level 1) 
targets; a 5-fold increase over expected from CCVs and 15-fold from HPPVs; p-value= 1×10-6; 
Supplementary Figure 4A). Notably, thirteen cancer driver genes (ATAD2, CASP8, CCND1, 
CHEK2, ESR1, FGFR2, GATA3, MAP3K1, MYC, SETBP1, TBX3, XBP1 and ZFP36L1) were 
predicted from the HPPVs derived from PAINTOR. Cancer driver gene status was 
consequently included as an additional weighting factor in the INQUISIT pipeline. TF genes 40 
were also enriched amongst high-confidence targets predicted from both CCVs (2-fold, p-
value = 4.6×10-4) and HPPVs (2.5-fold, p-value = 1.8×10-2, Supplementary Figure 4A). 
 
In total INQUISIT prioritized 191 high-confidence target genes (Supplementary Table 6). 
Significantly more genes were targeted by multiple independent signals (N = 165) than 
expected by chance (p-value = 4.3×10-8, Supplementary Figure 4B, Figure 4). Six high-
confidence predictions came only from HPPVs, although three of these (IGFBP5, POMGNT1 
and WDYHV1) had been predicted at lower confidence from CCVs. Target genes included 20 
that were prioritized via potential coding/splicing changes (Supplementary Table 7), ten via 
promoter variants (Supplementary Table 8), and 180 via distal regulatory variants 
(Supplementary Table 9). We illustrate genes prioritized via multiple lines of evidence in 
Figure 4A. 
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Three examples of INQUISIT using genomic features to identify predict target genes. Based 
on capture Hi-C and ChIA-PET chromatin interaction data, NRIP1 is a predicted target of 
intergenic CCVs and HPPVs at chr21q21 (Supplementary Figure 5A). Multiple target genes 
were predicted at chr22q12, including the driver genes CHEK2 and XBP1 (Supplementary 
Figure 5B). A third example at chr12q24.31 is a more complicated scenario with two Level 1 
targets: RPLP0 41 and a modulator of mammary progenitor cell expansion, MSI1 42 
(Supplementary Figure 5C). 
 
Target gene pathways include DNA integrity-checkpoint, apoptosis, developmental 
processes and the immune system 
We performed pathway analysis to identify common processes using INQUSIT high 
confidence target protein-coding genes (Figure 5A) and identified 488 Gene Ontology (GO) 
terms and 307 pathways at an FDR of 5% (Supplementary Table 10). These were grouped into 
98 themes by common ancestor GO terms, pathways, or TF classes (Figure 5B). We found that 
23% (14/60) of the ER-positive target genes were classified within developmental process 
pathways (including mammary development), 18% in immune system and a further 17% in 
nuclear receptors pathways. Of genes targeted by ER-neutral signals, 21% (18/87) were 
classified in developmental process pathways, 19% in in immune system pathways, and a 
further 18% in apoptotic process. The top themes of genes targeted by ER-negative signals 
were DNA integrity checkpoint and immune system, each containing 19% (7/37) genes, and 
apoptotic processes (16%). 
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Novel pathways revealed by this study include TNF-related apoptosis-inducing ligand (TRAIL) 
signaling, the AP-2 transcription factors pathway, and regulation of IB kinase/NF-B 
signaling. Of note, the latter of these is specifically overrepresented among ER-negative target 
genes. We also found significant overrepresentation of additional carcinogenesis-linked 
pathways including cAMP, NOTCH, PI3K, RAS, WNT/Beta-catenin, and of receptor tyrosine 
kinases signaling, including FGFR, EGFR, or TGFBR 43-47. Finally, our target genes are also 
significantly overrepresented in DNA damage checkpoint, DNA repair pathways, as well as 
programmed cell death pathways, such as apoptotic process, regulated necrosis, and death 
receptor signaling-related pathways. 
 
DISCUSSION 
We have performed multiple, complementary analyses on 150 breast cancer associated 
regions, originally found by GWAS, and identified 362 independent risk signals, 205 of these 
with high confidence (p-value < 10-6). The inclusion of these new variants increases the 
explained proportion of familial risk by 6% when compared to that explained by the lead 
signals alone.  
We observed most regions contain multiple independent signals, the greatest number (nine) 
in the region surrounding ESR1 and its co-regulated genes, and on 2q35, where IGFBP5 
appears to be a key target. We have used two complementary approaches to identify likely 
causal variants within each region: a Bayesian approach, PAINTOR, which integrated genetic 
associations, LD and informative genomic features, providing complementary evidence 
supporting most associations found by the more traditional, multinomial regression 
approach, and also identified additional variants. Specifically, the Bayesian method 
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highlighted 15 variants that are highly likely to be causal (HPP ≥ 80%). From these approaches 
we have identified a single variant, likely to be causal, at each of 34 signals (Table 1). Of these, 
only rs16991615 (MCM8 NP_115874.3:p.E341K) and rs7153397 (CCDC88C 
NM_001080414.2:c.5058+1342G>A, a cryptic splice-donor site) were predicted to affect 
protein-coding sequences. However, in other signals we also identified four coding changes 
previously recognized as deleterious, including the stop-gain rs11571833 (BRCA2 
NP_000050.2:p.K3326*, Meeks et al., 2016)48 and two CHEK2 coding variants; the frameshift 
rs555607708 49,50, and a missense variant, rs17879961 51,52. In addition, a splicing variant, 
rs10069690, in TERT results in the truncated protein INS1b 19, decreased telomerase activity, 
telomere shortening, and increased DNA damage response 53  
 
Having identified potential causal variants within each signal, we aimed to uncover their 
functions at the DNA level and as well as trying to predict their target gene(s). Looking across 
all 150 regions, a notable feature is that many likely causal variants implicated in ER-positive 
cancer risk, lie in gene-regulatory regions marked as open and active in ER-positive breast 
cells, but not in other cell types. Moreover, a significant proportion of potential causal 
variants overlap the binding sites for transcription factor proteins (n=40 from ChIP-Seq) and 
co-regulators (n=64 with addition of computationally derived motifs). Furthermore, nine 
proteins also appear in the list of high-confidence target genes, hence the following genes 
and their products have been implicated by two different approaches: CREBBP, EP300, ESR1, 
FOXI1, GATA3, MEF2B, MYC, NRIP1 and TCF7L2. Most proteins encoded by these genes 
already have established roles in estrogen signaling. CREBBP, EP300, ESR1, GATA3, and MYC 
are also known cancer driver genes that are frequently somatically mutated in breast tumors. 
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In contrast to ER-positive signals, we identified fewer genomic features enriched in ER-
negative signals. This may reflect the common molecular mechanisms underlying their 
development, but the power of this study was limited, despite including as many patients 
with ER-negative tumors as possible, from the BCAC and CIMBA consortia. Less than 20% of 
genomic signals confer a greater risk of ER-negative cancer and there is little publicly available 
ChIP-Seq data on ER-negative breast cancer cell lines. The heterogeneity of ER-negative 
tumors may also have limited our power. Nevertheless, we have identified 35 target genes 
for ER-negative likely causal variants. Some of these already had functional evidence 
supporting their role: including CASP8 54 and MDM4 55. Most targets, however, currently have 
no reported function in ER-negative breast cancer development. 
 
Finally, we examined the gene-ontology pathways in which target genes most often lie. Of 
note, 14% (25/180) of all high-confidence target genes and 19% of ER-negative target 
predictions are in immune system pathways. Among the significantly enriched pathways were 
T cell activation, interleukin signaling, Toll-like receptor cascades, and I-B kinase/NF-B 
signaling, as well as processes leading to activation and perpetuation of the innate immune 
system. The link between immunity, inflammation and tumorigenesis has been extensively 
studied 56, although not primarily in the context of susceptibility. Five ER-negative high 
confidence target genes (ALK, CASP8, CFLAR, ESR1, TNFSF10) lie in the I-B kinase/NF-B 
signaling pathway. Interestingly, ER-negative cells have high levels of NF-kB activity when 
compared to ER-positive 57. A recent expression–methylation analysis on breast cancer tumor 
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tissue also identified clusters of genes correlated with DNA methylation levels, one enriched 
in ER signaling genes, and a second in immune pathway genes 58. 
 
These analyses provide strong evidence for more than 200 independent breast cancer risk 
signals, identify the plausible cancer variants and define likely target genes for the majority 
of these. However, notwithstanding the enrichment of certain pathways and transcription 
factors, the biological basis underlying most of these signals remains poorly understood. Our 
analyses provide a rational basis for such future studies into the biology underlying breast 
cancer susceptibility. 
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METHODS 
Study samples 
Epidemiological data for European women were obtained from 75 breast cancer case-control studies 
participating in the Breast Cancer Association Consortium (BCAC) (cases: 40,285 iCOGS, 69,615 
OncoArray; cases with ER status available: 29,561 iCOGS, 55,081 OncoArray); controls: 38,058 iCOGS, 
50,879 OncoArray). Details of the participating studies, genotyping calling and quality control are given 
in 2,22,23, respectively. Epidemiological data for BRCA1 mutation carriers were obtained from 60 studies 
providing data to the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) (affected 
1,591 iCOGS, 7,772 OncoArray; unaffected 1,665 iCOGS, 7,780 OncoArray). This dataset has been 
described in detail previously 1,59,60. All studies provided samples of European ancestry. Any non-
European samples were excluded from analyses. 
 
Variant selection and genotyping  
Similar approaches were used to select variants for inclusion on the iCOGS and OncoArray, which are 
described in detail elsewhere 2,21. Both arrays including a dense coverage of variants across known 
susceptibility regions (at the time of their design), with sparser coverage of the rest of the genome.  
Twenty-one known susceptibility regions were selected for dense genotyping using iCOGS and 73 
regions using the Oncoarray: the regions were 1Mb intervals centred on the published lead GWAS hit 
(combined into larger intervals where these overlapped). For iCOGS: all known variants from the March 
2010 release of the 1000 Genomes Project with MAF > 0.02 in Europeans were identified, and all those 
correlated with the published GWAS variants at r2 > 0.1 together with a set of variants designed to tag 
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all remaining variants at r2 > 0.9 were selected to be included in the array. 
(http://ccge.medschl.cam.ac.uk/files/2014/03/iCOGS_detailed_lists_ALL1.pdf). For Oncoarray, all 
designable variants correlated with the known hits at r2 > 0.6, plus all variants from lists of potentially 
functional variants on RegulomeDB, and a set of variants designed to tag all remaining variants at r2 > 
0.9 were selected. In total, across the 152 regions considered here, 26,978 iCOGS and 58,339 OncoArray 
genotyped variants passed QC criteria.  
We imputed genotypes for all remaining variants using IMPUTE2 61 and the October 2014 release of the 
1000 Genomes Project as a reference. Imputation was conducted independently in the iCOGS and 
OncoArray subsets. To improve accuracy at low frequency variants, we used the standard IMPUTE2 
MCMC algorithm for follow-up imputation, which includes no pre-phasing of the genotypes and 
increasing both the buffer regions and the number of haplotypes to use as templates (more detailed 
description of the parameters used can be found in 21).  We thus genotyped or successfully imputed 
639,118 variants (all with imputation info score ≥ 0.3 and minor allele frequency (MAF) ≥ 0.001 in both 
iCOGS and OncoArray datasets). Imputation summaries, and coverage for each of the analyzed regions 
stratified by allele frequency can be found in Supplementary Table 1B. 
 
BCAC Statistical analyses 
Per-allele odds ratios (OR) and standard errors (SE) were estimated for each variant using logistic 
regression. We ran this analysis separately for iCOGS and OncoArray, and for overall, ER-positive and 
ER-negative breast cancer. The association between each variant and breast cancer risk was adjusted 
by study (iCOGS) or country (OncoArray), and eight (iCOGS) or ten (OncoArray) ancestry-informative 
principal components. The statistical significance for each variant was derived using a Wald test. 
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Defining appropriate significance thresholds for association signals 
To establish an appropriate significance threshold for independent signals, all variants evaluated in the 
meta-analysis were included in logistic forward selection regression analyses for overall breast cancer 
risk in iCOGS, run independently for each region. We evaluated five p-value thresholds for inclusion: < 
1×10−4, < 1×10-5, < 1×10-6, < 1×10-7, and < 1×10-8. The most parsimonious iCOGS models were tested in 
OncoArray, and the false discovery rate (FDR) at 1% level for each threshold estimated using the 
Benjamini-Hochberg procedure 63.  At a 1% FDR threshold: 72% of associations, significant at p<10-4, 
were replicated on iCOGS and 94% of associations, significant at p<10-6, were replicated on OncoArray. 
Based on these results, two categories were defined: strong-evidence signals (conditional p-values <10-
6 in the final model), and moderate-evidence signals (conditional p-values <10-4 and ≥10-6 in the final 
model) 
 
Identification of independent signals  
To identify independent signals, we ran multinomial stepwise regression analyses, separately in iCOGS 
and OncoArray, for all variants displaying evidence of association (Nvariants = 202,749). We selected two 
sets of well imputed variants (imputation info score ≥ 0.3 in both iCOGS and OncoArray): (a) common 
and low frequency variants (MAF ≥ 0.01) with logistic regression p-value inclusion threshold ≤0.05 in 
either the iCOGS or OncoArray datasets for at least one of the three phenotypes: overall, ER-positive 
and ER-negative breast cancer; and (b) rarer variants (MAF ≥ 0.001 and < 0.01), with logistic regression 
inclusion p-value ≤ 0.0001. The same parameters used for adjustment in logistic regression were used 
in the multinomial regression analysis (R function multinom). The multinomial regression estimates 
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were combined using a fixed-effects meta-analysis weighted by the inverse variance62. Variants with 
the lowest conditional p-value from the meta-analysis of both European cohorts at each step were 
included into the multinomial regression model. However, if the new variant to be included in the 
model caused collinearity problems due to high correlation with an already selected variant, or showed 
high heterogeneity (p-value < 10-4) between iCOGS and OncoArray after being conditioned by the 
variant(s) in the model; we dropped the new variant and repeated this process.  
 
At 105 of 152 evaluated regions the main signal demonstrated genome-wide significance, while 44 were 
marginally significant (9.89×10-5 ≥ p-value > 5×10-8). For two regions there were no variants significant 
at p<10-4 (chr14:104712261-105712261; rs10623258 multinomial regression p-value = 2.32×10-4; 
chr19:10923703-11923703, rs322144, multinomial regression p-value = 3.90×10-3). Four main 
differences in the datasets used here and in the previous paper may account for this: (i) our previous 
paper 2 included data from 11 additional GWAS (14,910 cases and 17,588 controls) that have not been 
included in the present analysis in order to minimize differences in array coverage, and because ER-
status data were substantially incomplete and individual level data were not available for all GWAS; (ii) 
the present analysis was based on estimating separate risks for ER-positive and ER-negative disease, 
whereas in our previous paper the outcome was overall breast cancer risk. ER status was available for 
only 73% of the iCOGS and 79% of the OncoArray breast cancer cases (iii) for the set of samples 
genotyped with both arrays, 2 used the iCOGS genotypes, while this study includes OncoArray 
genotypes to maximize the number of samples genotyped with a larger coverage; and (iv) the 
imputation procedure was modified (in particular using one-step imputation without pre-phasing) to 
improve the imputation accuracy of less frequent variants.  
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We used a forward stepwise approach to define the number of independent signals within each 
associated genomic region. We first we identified the index variant of the main signal in the region, and 
then ran multinomial logistic regression for all other variants, adjusted by the index variant, to identify 
additional variants that remained independently significant within the model. We repeated this 
process, adjusting for identified index variants, until no more additional variants could be added.  In 
this way we found from 1-11 independent signals within the 150 regions that containing a genome-
wide significant main signal.  
 
Selection of a set of credible causal variants (CCVs) 
For each independently associated signal, we first defined credible candidate variants (CCVs), likely to 
drive its association, as those variants with p-values within two orders of magnitude of the most 
significant variant for that signal, after adjusting for the index variant of other signals within that region 
(as identified in the forward stepwise regression above, Supplementary Figure 6A)24. For each region, 
we then attempted to obtain the best fitting model by successively fitting models in which the index 
variant for each signal was replaced by other CCVs for that signal, adjusting for the index variants for 
the other signals (Supplementary Figure 6B). Where a model with a higher chi-square was obtained, 
the index variant was replaced by the CCV in the best model (Supplementary Figure 6C-D). This process 
was repeated until the model (i.e. the set of index variants) did not change further (Supplementary 
Figure 6G). This procedure was performed first for the set of strong signals (i.e. considering models 
including only the strong signals). Once a final model had been obtained for the strong signals, the index 
variants for the strong signals were considered fixed and the process was repeated for all signals, the 
index variants for the weak signals (but not the strong signals) to vary. Using this procedure we could 
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define the best model for 140/150 regions, but for ten regions this approach did not converge 
(chr4:175328036-176346426, chr5:55531884-56587883, chr6:151418856-152937016, chr8:75730301-
76917937, chr10:80341148-81387721, chr10:122593901-123849324, chr12:115336522-116336522, 
chr14:36632769-37635752, chr16:3606788-4606788, chr22:38068833-39859355). For these 10 
regions, we defined the best model, from among all possible combinations of credible variants, as that 
with the largest chi-square value. Finally, redefined the set of CCVs for each signal using the conditional 
p-values, after adjusting for the revised set of index variants. Again, for the strong signals we 
conditioned on the index variants for the other strong signals, while for the weak signals we conditioned 
on the index variants for all other signals. 
 
Case-only analysis 
Differences in the effect size between ER-positive and ER-negative disease for each index independent 
variant were assessed using a case-only analysis. We performed logistic regression with ER status as the 
dependent variable, and the lead variant at each strong signal in the fine mapping region as the 
independent variables. We use FDR (5%) to adjust for multiple testing. 
 
OncoArray-only stepwise analysis 
To evaluate whether the lower coverage in iCOGS could affect the identification of independent signals, 
we ran stepwise multinomial regression using only the OncoArray dataset. We identified 249 
independent signals. Ninety-two signals, in 67 fine mapping regions, achieved a genome-wide 
significance level (conditional p-value < 5×10-8). Two hundred and five of these signals were also 
identified in the meta-analysis with iCOGS. Nine independent variants across ten regions were not 
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evaluated in the combined analysis due to their low imputation info score in iCOGS. Out of these nine 
signals, two signals would be classified as main primary signals, rs114709821 at region chr1:145144984-
146144984 (OncoArray imputation info score = 0.72), and rs540848673 at region chr1:149406413-
150420734 (OncoArray imputation info score = 0.33). Given the low number of additional signals 
identified in the OncoArray dataset alone, all analyses were based on the combined iCOGS/OncoArray 
dataset. 
 
CIMBA statistical analysis 
CIMBA provided data from 60 retrospective cohort studies consisting of 9,445 unaffected and 9,363 
affected female BRCA1 mutation carriers of European ancestry. Unconditional (i.e. single variant) 
analyses were performed using a score test based on the retrospective likelihood of observing the 
genotype conditional on the disease phenotype 63,64. Conditional analyses, where more than one 
variant is analyzed simultaneously, cannot be performed in this score test framework. Therefore, 
conditional analyses were performed by Cox regression, allowing for adjustment of the conditionally 
independent variants identified by the BCAC/DRIVE analyses. All models were stratified by country and 
birth cohort, and adjusted for relatedness (unconditional models used kinship adjusted standard errors 
based on the estimated kinship matrix; conditional models used cluster robust standard errors based 
on phenotypic family data). 
 
Data from the iCOGS array and the OncoArray were analyzed separately and combined to give an 
overall BRCA1 association by fixed-effects meta-analysis. Variants were excluded from further analyses 
if they exhibited evidence of heterogeneity (Heterogeneity p-value < 1×10-4) between iCOGS and 
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OncoArray, had MAF < 0.005, were poorly imputed (imputation info score < 0.3) or were imputed to 
iCOGS only (i.e. must have been imputed to OncoArray or iCOGS and OncoArray). 
 
Meta-analysis of ER-negative cases in BCAC with BRCA1 mutation carriers from CIMBA 
BRCA1 mutation carrier association results were combined with the BCAC multinomial regression ER-
negative association results in a fixed-effects meta-analysis. Variants considered for analysis must have 
passed all prior QC steps and have had MAF≥0.005. All meta-analyses were performed using the METAL 
software 65.Instances where spurious associations might occur were investigated by assessing the LD 
between a possible spurious association and the conditionally independent variants. High LD between 
a variant and a conditionally independent variant within its region causes model instability through 
collinearity and the convergence of the model likelihood maximization may not reliable. Where the 
association appeared to be driven by collinearity, the signals were excluded. 
 
Heritability Estimation 
To estimate the frailty-scale heritability due to all fine-mapping signals, we used the formula: 
ℎ2 = 2(𝛾′𝑇𝑅𝛾′ − 𝜏′𝑇𝐼𝜏′) 
here γ′ = γ√p(1 − p), τ′
T = τ√p(1 − p), where p is a vector of allele frequencies, γ are the estimated 
per-allele odds ratios and τ the corresponding standard errors, and 𝑅 is the correlation matrix of 
genotype frequencies. 
To adjust for the overestimation resulting from only including signals passing a given significance 
threshold, we adapted the approach of 66, based on maximizing the likelihood conditional on the test 
statistic passing the relevant threshold. Since our analyses were based on estimating ER-negative and 
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ER-positive odds ratios simultaneously, the method needed to be adapted to maximise a conditional 
bivariate normal likelihood. Following Zhong and Prentice (2008) we then estimated mean square error 
estimates based on a weighted mean of the maximum likelihood estimates and the naïve estimates, 
which they show to be close to be unbiased in the 1df case. The estimated effect sizes for overall breast 
cancer were computed as a weighted mean of the ER-negative and ER-positive estimates, based on the 
proportions of each subtype in the whole study (weights 0.21 and 0.79). The results were then 
expressed in terms of the proportion of the familial breast cancer risk (FRR) to first degree relatives of 
affected women, using the formula  
ℎ2/(2𝑙𝑜𝑔𝜆) where the FRR 𝜆 was assumed to be 2 2. 
 
eQTL analysis 
Total RNA was extracted from normal breast tissue in formalin-fixed paraffin embedded breast cancer 
tissue blocks from 264 Nurses’ Health Study (NHS) participants 32. Transcript expression levels were 
measured using the Glue Grant Human Transcriptome Array version 3.0 at the Molecular Biology Core 
Facilities, Dana-Farber Cancer Institute. Gene expression was normalized and summarized into Log2 
values using RMA (Affymetrix Power Tools v1.18.012); quality control was performed using GlueQC and 
arrayQualityMetrics v3.24.014. Genome-wide data on variants were generated using the Illumina 
HumanHap 550 BeadChip as part of the Cancer Genetic Markers of Susceptibility initiative 67. 
Imputation to the 1000KGP Phase 3 v5 ALL reference panel was performed using MACH to pre-phase 
measured genotypes and minimac to impute. 
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Expression analyses were performed using data from The Cancer Genome Atlas (TCGA) and Molecular 
Taxonomy of Breast Cancer International Consortium (METABRIC) projects 34,38. The TCGA eQTL analysis 
was based on 458 breast tumors that had matched gene expression, copy number and methylation 
profiles together with the corresponding germline genotypes available. All 458 individuals were of 
European ancestry as ascertained using the genotype data and the Local Ancestry in admixed 
Populations (LAMP) software package (LAMP estimate cut-off >95% European)68. Germline genotypes 
were imputed into the 1000 Genomes Project reference panel (October 2014 release) using IMPUTE 
version 2 69,70. Gene expression had been measured on the Illumina HiSeq 2000 RNA-Seq platform 
(gene-level RSEM normalized counts 71), copy-number estimates were derived from the Affymetrix SNP 
6.0 (somatic copy-number alteration minus germline copy-number variation called using the GISTIC2 
algorithm 72), and methylation beta values measured on the Illumina Infinium HumanMethylation450. 
Expression QTL analysis focused on all variants within each of the 152 genomic intervals that had been 
subjected to fine-mapping for their association with breast cancer susceptibility. Each of these variants 
was evaluated for its association with the expression of every gene within 2 Mb that had been profiled 
for each of the three data types. The effects of tumor copy number and methylation on gene expression 
were first regressed out using a method described previously 73. eQTL analysis was performed by linear 
regression, with residual gene expression as outcome, germline SNP genotype dosage as the covariate 
of interest and ESR1 expression and age as additional covariates, using the R package Matrix eQTL 74. 
 
The METABRIC eQTL analysis was based on 138 normal breast tissue samples resected from breast 
cancer patients of European ancestry. Germline genotyping for the METABRIC study was also done on 
the Affymetrix SNP 6.0 array, and gene expression in the METABRIC study was measured using the 
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Illumina HT12 microarray platform (probe-level estimates). No adjustment was implemented for 
somatic copy number and methylation status since we were evaluating eQTLs in normal breast tissue. 
All other steps were identical to the TCGA eQTL analysis described above. 
 
Genomic feature enrichment  
We explored the overlap of CCVs and excluded variants with 90 transcription factors, 10 histone 
marks, and DNase hypersensitivity sites in in 15 breast cell lines, and eight normal human breast 
tissues. We analysed data from the Encyclopedia of DNA Elements (ENCODE) Project 75,76, Roadmap 
Epigenomics Projects 77, the International Human Epigenome Consortium 78, 27, 79, The Cancer Genome 
Atlas (TCGA) 33, the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) 34, 
ReMap database (We included 241 TF annotations from ReMap (of 2825 total) which showed at least 
2% overlap for any of the phenotype SNP sets) 80, and other data obtained through the National 
Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO). Promoters were 
defined following the procedure defined in Pellacani et al. 79, that is +/- 2Kb from a gene transcription 
start site, using an updated version of the RefSeq genes (refGene, version updated 2017-04-11)81. 
Transcribed regions were defined using the same version of refSeq genes. lncRNA annotation was 
obtained from Gencode (v19)82 
 
To include eQTL results in the enrichment analysis we (i) identified all the genes for which summary 
statistics were available; (ii) defined the most significant eQTL variant for each gene (index eQTL variant, 
p-value threshold ≤ 5×10-4); (iii) classified variants with p-values within two orders of magnitude of the 
index eVariant as the credible set of eQTL variants; ie. the best candidates to drive expression of the 
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gene. Variants within at least one eQTL credible set were defined as eVariants. We evaluated the 
overlap between eQTL credible sets and CCVs (risk variants credible set). We evaluated the enrichment 
of CCVs for genomic feature using logistic regression, with CCV (vs non-CCV variants) being the 
outcome. To adjust for the correlation among variants in the same fine mapping region, we used robust 
variance estimation for clustered observations (R function multiwaycov). The associated variants at FDR 
5% were included into a stepwise forward logistic regression procedure to select the most parsimonious 
model. A likelihood ratio test was used to compare multinomial logistic regression models with and 
without equality effect constraints to evaluate whether there was heterogeneity among the effect sizes 
for ER-positive, ER-negative or signals equally associated with both phenotypes (ER-neutral). 
 
To validate the disease specificity of the regulatory regions identified through this analysis we follow 
the same approach for the autoimmune related CCVs from 29 (N = 4,192). Variants excluded as 
candidate causal variants, and within 500 kb upstream and downstream of the index variant for each 
signal were classified as excluded variants (N = 1,686,484). We then tested the enrichment for both the 
breast cancer and autoimmune CCVs with breast and T and B cell enhancers. We also evaluated the 
overlap of our CCVs with ENCODE enhancer-like and promoter-like regions for 111 tissues, primary cells, 
immortalized cell line, and in vitro differentiated cells. Of these, 73 had available data for both 
enhancer- and promoter-like regions. 
 
Transcription binding site motif analysis 
We conducted a search to find motif occurrences for the transcription factors significantly enriched in 
the genomic featured. For this we used two publicly available databases, Factorbook 83 and JASPAR 
 65 
2016 84. For the search using Factorbook we included the motifs for the transcription factors discovered 
in the cell lines where a significant enrichment was found in our genomic features analysis. We also 
searched for all the available motifs for Homo sapiens at the JASPAR database (JASPAR CORE 2016, 
TFBSTools 85)Using as reference the USCS sequence (BSgenome.Hsapiens.USCS.hg19) we created fasta 
sequences with the reference and alternative alleles for all the variants included in our analysis plus 20 
bp flanking each variant. We used FIMO (version 4.11.2, Grant et al., 2011)86 to scan all the fasta 
sequences searching for the JASPAR and Factorbook motifs to identify any overlap of any of the alleles 
for each of the variants (setting the p-value threshold to 10-3). We subsequently determined whether 
our CCVs were more frequency overlapping a particular TF binding motif when compared with the 
excluded variants. We ran these analyses for all the strong signals, but also strong signals stratified by 
ER status. Also, we subset this analysis to the variants located at regulatory regions in an ER-positive 
cell line (MCF-7 marked by H3K4me1, ENCODE id: ENCFF674BKS) and evaluated whether the ER-
positive CCVs overlap any of the motifs more frequently that the excluded variants. We also evaluated 
the change in total binding affinity caused by the ER-positive CCCR alternative allele for all but one 
(2:217955891:T:<CN0>:0) of the ER-positive CCVs (MatrixRider 87). 
 
Subsequently, we evaluated whether the MCF-7 regions demarked by H3K4me1 (ENCODE id: 
ENCFF674BKS), and overlapped by ER-positive CCVs, were enriched in known TFBS motifs. We first 
subset the ENCODE bed file ENCFF674BKS to identify MCF-7 H3K4me1 peaks overlapped by the ER-
positive CCVs (N = 107), as well as peaks only overlapped by excluded variants (N = 11,099), using 
BEDTools 88. We created fasta format sequences using genomic coordinate data from the intersected 
bed files. In order to create a control sequence set, we used the script included with the MEME Suite 
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(fasta-shuffle-letters) to created 10 shuffled copies of each sequence overlapped by ER-positive CCVs 
(N = 1,070). We then used AME 89 to interrogate whether the 107 MCF-7 H3K4me1 genomic regions 
overlapped by ER-positive CCVs were enriched in know TFBS consensus motifs when compared to the 
shuffled control sequences, or to the MCF-7 H3K4me1 genomic regions overlapped only by excluded 
variants. We used the command line version of AME (version 4.12.0) selecting as scoring method the 
total number of positions in the sequence whose motif score p-value is less than 10-3, and using a one-
tailed Fisher’s Exact test as the association test. 
 
PAINTOR analysis 
To further refine the set of CCVs, we performed empirical Bayes fine-mapping using PAINTOR to 
integrate marginal genetic association summary statistics, linkage disequilibrium patterns, and 
biological features 31,90. PAINTOR derives jointly the posterior probability for causality of all variants 
along the respective contribution of genomic features, in order to maximize the log Likelihood of the 
data across all regions. PAINTOR does not assume a fixed number of causal variants in each region, 
although it implicitly penalizes non-parsimonious causal models. We applied PAINTOR separately to 
association results for overall breast cancer (in 85 regions determined to have at least one ER-neutral 
association or ER-positive and ER-negative association), ER-positive breast cancer (in 48 regions 
determined to have at least one ER-positive-specific association), and ER-negative breast cancer (in 22 
regions determined to have at least one ER-negative-specific association). To avoid artifacts due to mis-
matches between the LD in study samples and the LD matrix supplied to PAINTOR, we used association 
logistic regression summary statistics from OncoArray data only and estimated the LD structure in the 
OncoArray sample. For each endpoint we fit four models with increasing numbers of genomic features 
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selected from the stepwise enrichment analyses described above: Model 0 (with no genomic features—
assumes each variant is equally likely to be causal a priori), Model 1 (with those genomic features 
selected with stopping rule p<0.001); Model 2 (with those genomic features selected with stopping rule 
p<0.01); and Model 3 (with those genomic features selected with stopping rule p<0.05).  
 
We used the Bayesian Information Criterion (BIC) to choose the best-fitting model for each outcome. 
As PAINTOR estimates the marginal log likelihood of the observed Z scores using Gibbs sampling, we 
used a shrunk mean BIC across multiple Gibbs chains to account for the stochasticity in the log-
likelihood estimates. We ran PAINTOR four times to generate four independent Gibbs chains and 
estimated the BIC difference between model i and model j as 𝛥𝑖𝑗 = (
100
𝑉+100
) (𝐵𝐼𝐶𝑖´ − 𝐵𝐼𝐶𝑗´ ). This 
assumes a N(0,100) prior on the difference, or roughly a 16% chance that model i would be decisively 
better than model j (i.e. |BICi-BICj|>10). We then proceeded to choose the best-fitting model in a 
stepwise fashion: starting with a model with no annotations, we selected a model with more 
annotations in favor a model with fewer if the larger model was a considerably better fit—i.e. 𝛥𝑖𝑗  > 2. 
Model 1 was the best fit according to this process for overall and ER-positive breast cancer; Model 0 
was the best fit for ER-negative breast cancer.  
 
Differences between the PAINTOR and CCV outputs may be due to several factors. By considering 
functional enrichment and joint LD among all SNPs, PAINTOR may refine the set of likely causal variants; 
rather than imposing a hard threshold, PAINTOR allows for a gradient of evidence supporting causality; 
and the two sets of calculations are based on different summary statistics, CCV analyses used both 
iCOGS and OncoArray genotypes, while PAINTOR used only OncoArray data (Figure 1, Methods). 
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Variant annotation 
Variants genome coordinates were converted to assembly GRCh38 with liftOver and uploaded to 
Variant Effect Predictor 91 to determine their effect on genes, transcripts, and protein sequence. The 
commercial software Alamut® Batch v1.6 batch was also used to annotate coding and splicing variants. 
PolyPhen-2 92, SIFT 93, MAPP 94 were used to predict the consequence of missense coding variants. 
MaxEntScan 95, Splice-Site Finder, and Human Splicing Finder 96 were used to predict splicing effects. 
 
INQUISIT analysis 
Logic underlying INQUISIT predictions 
Briefly, genes were considered to potential targets of candidate causal variants through effects on: (1) 
distal gene regulation, (2) proximal regulation, or (3) a gene's coding sequence. We intersected CCV 
positions with multiple sources of genomic information including chromatin interactions from capture 
Hi-C experiments performed in a panel of six breast cell lines 97, chromatin interaction analysis by 
paired-end tag sequencing (ChIA-PET; 98) and genome-wide chromosome conformation capture from 
HMECs (Hi-C, (Rao et al., 2014)). We used computational enhancer–promoter correlations (PreSTIGE 99, 
IM-PET (He et al., 2014), FANTOM5 100 and super-enhancers 28), results for breast tissue-specific 
expression variants (eVariants) from multiple independent studies (TCGA, METABRIC, NHS, Methods), 
allele-specific imbalance in gene expression 101, transcription factor and histone modification chromatin 
immunoprecipitation followed by sequencing (ChIP-Seq) from the ENCODE and Roadmap Epigenomics 
Projects together with the genomic features found to be significantly enriched as described above, gene 
expression RNA-seq from several breast cancer lines and normal samples and topologically associated 
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domain (TAD) boundaries from T47D cells (ENCODE, 102, Methods and Key Resources Table ). To assess 
the impact of intragenic variants, we evaluated their potential to alter splicing using Alamut® Batch to 
identify new and cryptic donors and acceptors, and several tools to predict effects of coding sequence 
changes (see Variant Annotation section). Variants potentially affecting post-translational 
modifications were downloaded from the "A Website Exhibits SNP On Modification Event" database 
(http://www.awesome-hust.com/) 103.  The output from each tool was converted to a binary measure 
to indicate deleterious or tolerated predictions. 
 
Scoring hierarchy 
Each target gene prediction category (distal, promoter or coding) was scored according to different 
criteria. Genes predicted to be distally-regulated targets of CCVs were awarded points based on physical 
links (eg CHi-C), computational prediction methods, allele-specific expression, or eVariant associations. 
All CCV and HPPVs were considered as potentially involved in distal regulation. Intersection of a putative 
distal enhancer with genomic features found to be significantly enriched (see ‘Genomic features 
enrichment’ for details) were further upweighted. Multiple independent interactions were awarded an 
additional point. CCVs and HPPVs in gene proximal regulatory regions were intersected with histone 
ChIP-Seq peaks characteristic of promoters and assigned to the overlapping transcription start sites 
(defined as -1.0 kb - +0.1 kb). Further points were awarded to such genes if there was evidence for 
eVariant association or allele-specific expression, while a lack of expression resulted in down-weighting 
as potential targets. Potential coding changes including missense, nonsense and predicted splicing 
alterations resulted in addition of one point to the encoded gene for each type of change, while lack of 
expression reduced the score. We added an additional point for predicted target genes that were also 
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breast cancer drivers. For each category, scores ranged from 0-7 (distal); 0-3 (promoter) or 0-2 (coding). 
We converted these scores into 'confidence levels': Level 1 (highest confidence) when distal score > 4, 
promoter score >= 3 or coding score > 1; Level 2 when distal score <=  4 and >=1, promoter score = 1 or 
= 2, coding score = 1; and Level 3 when distal score < 1 and > 0, promoter score < 1 and > 0, and coding 
< 1 and > 0. For genes with multiple scores (for example, predicted as targets from multiple independent 
risk signals or predicted to be impacted in several categories), we recorded the highest score. Driver 
and transcription factor gene enrichment analysis was carried out using INQUISIT scores prior to adding 
a point for driver gene status. Modifications to the pipeline since original publication 2 include: 
 TAD boundary definitions from ENCODE T47D Hi-C analysis. Previously, we used regions from Rao, 
Cell 2013; 
 eQTL: Addition of NHS normal and tumor samples 
 allele-specific imbalance using TCGA and GTEx RNA-seq data 101 
 Capture Hi-C data from six breast cell lines 104 
 Additional biofeatures derived from global enrichment in this study 
 Variants affecting sites of post-translational modification 103 
 
Multi-signal targets 
To test if more genes were targeted by multiple signals than expected by chance, we modelled the 
number of signals per gene by negative binomial regression (R function glm.nb, package MASS) and 
Poisson regression (R function glm, package stats) with ChIA-PET interactions as a covariate and 
adjusted by fine mapping region. Likelihood ratio tests were used to compare goodness of fit. 
Rootograms were created using the R function rootogram (package vcd).  
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Pathway analysis 
The pathway gene set database, dated 1 September 2018 was used 105 
(http://download.baderlab.org/EM_Genesets/current_release/Human/symbol/). This database 
contains pathways from Reactome 106, NCI Pathway Interaction Database 107, GO (Gene Ontology) 108, 
HumanCyc 109, MSigdb 110, NetPath 111, and Panther 112. All duplicated pathways, defined in two or more 
databases, were included. To provide more biologically meaningful results, only pathways that 
contained ≤ 200 genes were used.  
We interrogated the pathway annotation sets with the list of high-confidence (Level 1) INQUISIT gene 
list. The significance of over-representation of the INQUISIT genes within each pathway was assessed 
with a hypergeometric test, 113, using the R function phyper as follows: 
𝑃(𝑥|𝑛,𝑚,𝑁) = 1 −∑
(𝑚
𝑖
)(𝑁−𝑚
𝑛−𝑖
)
(𝑁
𝑛
)
𝑥−1
𝑖=0
 
where x is the number of Level 1 genes that overlap with any of the genes in the pathway, n is the 
number of genes in the pathway, m is the number of Level1 genes that overlap with any of the genes 
in the pathway data set (mstrong GO = 145, mER-positive GO = 50, mER-negative GO = 27, mER-neutral GO = 73; mstrong 
Pathways = 121, mER-positive Pathways = 38, mER-negative Pathways = 21, mER-neutral Pathways = 68), and N is the number 
of genes in the pathway data set (NGenes GO = 14,252, NGenes Pathways = 10,915). We only included pathways 
that overlapped with at least two Level 1 genes. We used the Benjamini-Hochberg false discovery rate 
(FDR) 114 at 5% level.  
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FIGURE LEGENDS 
Figure 1. Flowchart summarizing the study design. 
Logistic regression summary statistics were used to select the final set of variants to run stepwise 
multinomial regression. These results were meta-analysed with CIMBA to provide the final set of 
strong independent signals and their CCVs. Through a case-only analysis we identified significant 
differences in effect sizes between ER-positive and ER-negative breast cancer and used this to 
classify the phenotype for each independent signal. With these strong CCVs, we ran the bio-
features enrichment analysis, which identified the features to be included in the PAINTOR 
models, together with the OncoArray logistic regression summary statistics, and the OncoArray 
LD. Both multinomial regression CCVs and PAINTOR high Posterior Probability variants were 
analyzed with INQUISIT to determine high confidence target genes. Finally, we used the set of 
high confidence target genes to identify enriched pathways. 
a  conditional on the index variants from BCAC strong signals. 
 
Figure 2. Determining independent risk signals and credible candidate variants (CCVs). 
(a) Number of independent signals per region identified through multinomial stepwise logistic 
regression. (b) Signal classification according to their confidence into strong and moderate 
confidence signals. (c) Number of CCVs per signal at strong confidence signals identified through 
multinomial stepwise logistic regression. (d) Number of CCVs per signal at moderate confidence 
signals identified through multinomial stepwise regression. (e) Subtype classification of strong 
signals into ER-positive, ER-negative and signals equally associated with both phenotypes (ER-
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neutral) from BCAC analysis. (f) Subtype classification from the meta-analysis of BCAC and CIMBA. 
Between brackets, number of CCVs from the meta-analysis of BCAC and CIMBA. (g) Number of 
variants at different posterior probability thresholds. 15 variants reach a PP ≥ 80% by at least one 
of the three models (ER-all, ER-positive, ER-negative). 
 
Figure 3. Overlap of CCVs with gene regulatory regions gene bodies and transcription factor 
binding sites. 
(a) Breast cancer CCVs overlap with chromatin states and broad breast cells epigenetic marks. (b) 
Breast cancer CCVs overlap with breast cells epigenetic marks. (c) Autoimmune CCVs overlap with 
breast cells epigenetic marks. (d) Breast cancer CCVs overlap with autoimmune-related 
epigenetic marks. (e) Autoimmune CCVs overlap with autoimmune-related epigenetic marks. (f) 
Significant ER-positive CCVs overlap with transcription factors binding sites. TFBSs found 
significant for ER-positive CCVs are highlighted in red (x axis labels). (g) Significant ER-negative 
CCVs overlap with transcription factors binding sites. (h) Significant ER-neutral CCVs overlap with 
transcription factors binding sites. Strong column: analysis with all CCVs at strong signals. ER-
positive, ER-negative, ER-neutral: analysis of CCVs at strong signals stratified by phenotype. 
Logistic regression robust variance estimation for clustered observations, Wald test 2 p-values 
estimated using 67,136 ER-positive and 17,506 ER-negative cases, together with 88,937 controls. 
Non-significant p-values are noted as dark grey. Significance defined as FDR 5%, which 
corresponds to the following P-value thresholds: Strong signals P-value = 1.66x10-2, ER-positive 
P-value = 2.42x10-2; ER-negative P-value 3.02x10-3; ER-neutral P-value = 1.76x10-3.  
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Figure 4. Predicted target genes are enriched in known breast cancer driver genes and 
transcription factors. 
79 target genes that fulfil at least one of the following criteria: are targeted by more than one 
independent signal, are known driver genes, transcription factor genes, or their binding sites 
(ChIP-Seq BS) or consensus motif (TF Motif) are significantly overlapped by CCVs. *Genes with 
published functional follow up.  
 
Figure 5. Predicted target genes by phenotype and significantly enriched pathways. 
(a) Venn diagram showing the associated phenotype (ER-positive, ER-negative, ER-neutral) for 
the Level 1 target genes, predicted by the CCVs and HPPVs. * ER-positive or ER-negative target 
genes also targeted by ER-neutral signals. (b) Heatmap showing clustering of pathway themes 
over-represented by INQUISIT Level 1 target genes. Color represents the relative number of 
genes per phenotype within enriched pathways, grouped by common themes. ER-positive, ER-
negative, ER-neutral, and all phenotypes together (strong).
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Table 1. Signals with single CCVs and variants with PP > 80%  
                ER-negative  ER-positive       
Fine-mapping 
regiona 
Variant b Ref/Alt c EAFd PPe Modelf Signalg 
N 
CCVh 
ORi (95%CI) ORi (95%CI) P-valuei FPj 
Predicted 
target gene(s)k 
chr1:120723447 
-121780613 
rs11249433 A/G 0.42 0.57 ERALL Signal 1 1 1.02 (0.99-1.04) 1.13 (1.11-1.15) 8.11x10-60 na na 
chr1:200937832 
-201937832 
rs35383942 C/T 0.06 0.96 ERALL Signal 1 2 1.10 (1.05-1.16) 1.09 (1.06-1.13) 1.14x10-7 D TNNI1 
chr2:201681247 
-202681247 
rs3769821 C/T 0.66 0.40 ERALL Signal 1 1 0.94 (0.92-0.97) 0.95 (0.93-0.96) 1.46x10-12 D ALS2CR12 
chr2:217405832 
-218796508 
rs4442975 n G/T 0.48 0.84 ERALL Signal 1 1 0.94 (0.92-0.97) 0.86 (0.85-0.87) 2.50x10-90 D IGFBP5m 
chr4:105569013 
-106856761 
esv3601665 -/Alu 0.07 0.95 ERPOS   1.01 (0.95-1.08) 1.10 (1.06-1.14) 3.27x10-6 D ARHGEF38, AC004066.3 
chr5:779790 
-1797488 
rs10069690 C/T 0.27 0.58 ERNEG Signal 1 1 1.18 (1.15-1.21) 1.03 (1.01-1.05) 1.20x10-34 D SLC6A18, TERTm 
chr5:44013304 
-45206498 
rs10941679 A/G 0.26 0.00 ERPOS Signal 1 1 1.04 (1.02-1.07) 1.17 (1.15-1.19) 1.50x10-77 D MRPS30 
 rs5867671 A/- 0.77 0.01 ERPOS Signal 2 1 0.91 (0.89-0.94) 0.99 (0.97-1.01) 2.25x10-9 na na 
chr5:44013304 
-45206498 
rs190443933 T/C 0.01 0.00 ERALL Signal 4 1 1.30 (1.14-1.48) 1.26 (1.16-1.37) 2.32x10-8 na na 
chr5:55531884 
-56587883 
rs984113 G/C 0.61 0.81 ERPOS Signal 2 1 0.96 (0.93-0.98) 0.96 (0.94-0.97) 3.51x10-8 D MAP3K1m 
 
 
rs889310 C/T 0.56 0.84 ERPOS (Signal 6) 15 1.03 (1.00-1.05) 1.05 (1.03-1.06) 1.75x10-7 D MAP3K1m 
chr6:15899557 
-16899557 
rs3819405 C/T 0.32 0.96 ERALL Signal 1 1 0.97 (0.95-1.00) 0.95 (0.94-0.97) 1.14x10-7 D 
ATXN1, RP1-151F17.1, 
RP1-151F17.2 
chr6:151418856 
-152937016 
rs12173562 C/T 0.08 0.10 ERNEG Signal 1 1 1.30 (1.25-1.36) 1.14 (1.11-1.18) 3.98x10-40 D ESR1m 
 rs34133739 -/C 0.53 0.25 ERALL Signal 2 1 1.11 (1.09-1.14) 1.05 (1.04-1.07) 2.36x10-22 D ESR1m 
 rs851984 G/A 0.40 0.73 ERALL Signal 3 1 1.07 (1.04-1.09) 1.05 (1.04-1.07) 3.69x10-13 D ESR1m 
chr7:130167121 
-131167121 
rs68056147 G/A 0.30 0.84 ERALL   1.04 (1.01-1.07) 1.05 (1.03-1.06) 3.07x10-7 D MKLN1 
chr8:127424659 
-130041931 
rs35961416 -/A 0.41 0.68 ERALL Signal 3 1 0.97 (0.94-0.99) 0.95 (0.93-0.96) 9.97x10-11 D MYCm 
chr9:21247803 
-22624477 
rs539723051 AAAA/- 0.33 0.43 ERALL Signal 1 1 1.08 (1.05-1.11) 1.06 (1.04-1.08) 1.81x10-15 na na 
chr9:109803808 
-111395353 
rs10816625 A/G 0.07 0.95 ERPOS Signal 3 1 1.06 (1.01-1.11) 1.13 (1.10-1.16) 3.62x10-15 D KLF4m 
 rs13294895 C/T 0.18 0.93 ERPOS Signal 4 1 1.01 (0.98-1.05) 1.09 (1.07-1.11) 4.00x10-17 D KLF4m 
chr9:109803808 
-111395353 
rs60037937 AA/- 0.22 0.68 ERPOS Signal 2 1 1.02 (0.99-1.06) 1.11 (1.09-1.13) 3.17x10-26 D KLF4m, RAD23B 
chr10:63758684 
-65063702 
rs10995201 A/G 0.15 0.31 ERALL Signal 1 1 0.91 (0.88-0.94) 0.87 (0.85-0.89) 1.40x10-37 na na 
chr10:122593901 
-123849324 
rs35054928 C/- 0.56 0.60 ERALL Signal 1 1 0.96 (0.94-0.98) 0.74 (0.73-0.76) 6.55x10-342 D FGFR2m 
 rs45631563 n A/T 0.04 0.93 ERPOS Signal 3 1 0.97 (0.92-1.03) 0.76 (0.73-0.79) 4.84x10-44 C FGFR2m 
 rs7899765 T/C 0.06 0.02 ERALL Signal 5 1 1.01 (0.97-1.06) 0.87 (0.84-0.90) 2.21x10-18 D FGFR2m 
chr11:68831418 
-69879161 
rs78540526 C/T 0.09 0.91 ERPOS Signal 1 1 1.01 (0.97-1.06) 1.40 (1.36-1.44) 2.77x10-145 D CCND1m, MYEOV 
chr12:27639846 
-29034415 
rs7297051 C/T 0.23 0.23 ERALL Signal 1 1 0.87 (0.85-0.90) 0.89 (0.88-0.91) 3.12x10-43 D 
CCDC91m, PTHLHm, 
RP11-967K21.1 
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chr12:115336522 
-116336522 
rs35422 G/A 0.57 0.58 ERPOS Signal 2 1 0.98 (0.96-1.01) 1.05 (1.03-1.07) 4.85x10-10 D TBX3 
chr14:91341069 
-92368623 
rs7153397 C/T 0.70 0.81 ERPOS Signal 1 3 1.01 (0.99-1.04) 1.06 (1.04-1.08) 3.25x10-11 D,C 
CCDC88C, CTD-2547L24.4, 
C14orf159, GPR68, RPS6KA5, 
RP11-73M18.7, RP11-895M11.3 
chr16:52038825 
-53038825 
rs4784227 C/T 0.27 0.95 ERPOS Signal 1 1 1.15 (1.12-1.18) 1.26 (1.24-1.28) 4.63x10-160 D TOX3m 
chr18:23832476 
-25075396 
rs180952292 T/C 0.01 0.01 ERNEG Signal 4 1 1.24 (1.12-1.37) 0.98 (0.92-1.05) 2.07x10-5 na na 
chr18:41899590 
-42899590 
rs9952980 T/C 0.34 0.95 ERALL Signal 2 3 0.97 (0.94-0.99) 0.95 (0.93-0.96) 7.43x10-12 D SLC14A2 
chr20:5448227 
-6448227 
rs16991615 G/A 0.07 0.97 ERALL Signal 1 1 1.09 (1.04-1.15) 1.07 (1.04-1.11) 7.89x10-7 D, C GPCPD1, MCM8 
chr22:45783297 
-46783297 
rs184070480 C/T 0.01 0.00 ERALL Signal 2 1 1.40 (1.20-1.64) 1.01 (0.91-1.12) 5.02x10-5 D ATXN10, WNT7B 
 
a GRCh37/hg19, bp 
b Current reference ID  
c Reference (Ref) versus Alternative (Alt) Allele 
d Effect allele (Alt allele) frequency in OncoArray 
e PP: Posterior probability. Largest posterior probability in all evaluated models 
f Model where the variant reaches the largest posterior probability 
g Signal where the variant is included. Between brackets moderate confidence signals. 
h Number of CCVs in the signal 
i Multinomial logistic regression summary statistics, 2 single variant analysis p-value, estimated 
using 67,136 ER-positive and 17,506 ER-negative cases, together with 88,937 controls.  
j D: Distal regulation, P: proximal regulation, C: coding; na: prediction non available 
k Predicted target genes with the largest confidence level for each variant. Between brackets, 
largest confidence level. na: prediction non available 
l INQUISIT level of confidence 
m Target genes with functional follow up 
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n Two variants reach PP> 0.8 in both the ERall and ERpos models; rs4442975: ERpos PP = 0.83, 
ERall PP = 0.84; rs45631563: ERpos PP = 0.93, ERall PP = 0.92 
